Bionomics Faces Nasdaq Delisting Warning

TL;DR

Nasdaq's giving Bionomics a deadline to fix its stock price or get booted.

AI Summary

Bionomics Limited announced on July 11, 2024, that it received a notice from the Nasdaq Stock Market regarding its failure to meet the minimum bid price requirement for continued listing. The company has until January 7, 2025, to regain compliance.

Why It Matters

This filing indicates Bionomics Limited may be delisted from the Nasdaq, potentially impacting its stock liquidity and investor confidence.

Risk Assessment

Risk Level: medium — The company is at risk of delisting from a major stock exchange if it cannot meet the minimum bid price requirement.

Key Numbers

• January 7, 2025 — Compliance Deadline (The date by which Bionomics must regain compliance with Nasdaq's minimum bid price rule.)

Key Players & Entities

• Bionomics Limited (company) — Registrant
• Nasdaq Stock Market (company) — Exchange issuing notice
• July 11, 2024 (date) — Date of notice
• January 7, 2025 (date) — Compliance deadline

FAQ

Key Financial Figures

• $1.00 — y did not meet the minimum bid price of $1.00 per share required for continued listin

Filing Documents

• ea0209330-8k_bionomic.htm (8-K) — 27KB
• 0001213900-24-061529.txt ( ) — 197KB
• bnox-20240711.xsd (EX-101.SCH) — 3KB
• bnox-20240711_lab.xml (EX-101.LAB) — 33KB
• bnox-20240711_pre.xml (EX-101.PRE) — 22KB
• ea0209330-8k_bionomic_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to Satisfy a Continued

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 11, 2024, Bionomics Limited (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that, based upon the closing bid price of the Company's American Depositary Shares (the "Shares") for the 30 consecutive business days between May 28, 2024 and July 10, 2024, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until January 7, 2025 (the "Compliance Period"), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). In order to regain compliance with Nasdaq's minimum bid price requirement, the Company's Shares must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the Compliance Period. In the event the Company does not regain compliance by the end of the Compliance Period, the Company may be eligible for additional time to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for The Nasdaq Global Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company meets these requirements, including providing timely notice and paying a transfer and application fee, if and as applicable, the Company may be granted an additional 180 calendar days to regain compliance. However, if it appears to Nasdaq that the Company will be unable to cure the deficiency, or if the Company is not otherwise eli

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIONOMICS LIMITED Date: July 16, 2024 By: /s/ Spyros Papapetropoulos Name: Spyros Papapetropoulos Title: President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR